X

Journal of Hematology & Oncology

Journal of Hematology & Oncology
Anti-PD-1 Antibodies as a Salvage Therapy for Patients With Diffuse Large B Cell Lymphoma Who Progressed/Relapsed After CART19/20 Therapy

In this study, investigators analyze data from five patients with R/R DLBCL who had disease progression or relapse following CART19/20 therapy and then treated with PD-1-blocking antibodies...

Journal of Hematology & Oncology
07/05/2021
Allogeneic Hematopoietic Cell Transplantation With Cord Blood Versus Mismatched Unrelated Donor With Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia

Study investigators compare the allo-HCT outcomes of CBT versus single-allele-mismatched MMUD allo-HCT with post-transplant cyclophosphamide in acute myeloid leukemia.

Journal of Hematology & Oncology
05/03/2021
Targeting the Metabolic Vulnerability of Acute Myeloid Leukemia Blasts With a Combination of Venetoclax and 8-Chloro-Adenosine

BCL‐2 inhibition through venetoclax targets acute myeloid leukemia blast cells and leukemic stem cells.

Journal of Hematology & Oncology
04/26/2021
Prostate Cancer and PARP Inhibitors: Progress and Challenges

In solid tumors, the first demonstration of an improvement in overall survival is provided by olaparib in patients with mCRPC harboring homologous recombination repair deficiencies.

Journal of Hematology & Oncology
03/29/2021
Novel Agents and Regimens for Hematological Malignancies: Recent Updates From 2020 ASH Annual Meeting

This study summarizes the latest updates on novel agents and regimens for hematological malignancies from the 2020 ASH annual meeting.

Journal of Hematology & Oncology
04/21/2021
Therapeutic Strategies in RET Gene Rearranged Non-Small-Cell Lung Cancer

The results from the LIBRETTO-001 and ARROW clinical trials demonstrate significant clinical benefits with selpercatinib and pralsetinib respectively, in NSCLC patients with RET gene fusions...

Journal of Hematology & Oncology
03/26/2021
Targeting Bruton Tyrosine Kinase Using Non-covalent Inhibitors in B Cell Malignancies

This review discusses the rationale for the use of non-covalent BTK inhibitors and the preclinical and clinical studies of non-covalent BTK inhibitors in B cell malignancies.

Journal of Hematology & Oncology
03/06/2021
Preclinical Evaluation of the Hsp90 Inhibitor SNX-5422 in Ibrutinib Resistant CLL

This study explores the efficacy of the Hsp90 inhibitor, SNX-5422, in CLL.

Journal of Hematology & Oncology
02/24/2021
Subscribe to Journal of Hematology & Oncology

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834